Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 158-163 , May 2007

A case-control study of apoA5 −1131T→C polymorphism that examines the role of triglyceride levels in diabetic nephropathy

Received 2 November 2005 ,Revised 8 February 2006 ,Accepted 14 February 2006.

References 

  1. Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, et al. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arteriosclerosis Thrombosis & Vascular Biology. 2004;24:1297–1302
  2. Baum L, Tomlinson B, Thomas GN. APOA5−1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clinical Genetics. 2003;63:377–379
  3. Bi N, Yan SK, Li GP, Yin ZN, Chen BS. A single nucleotide polymorphism −1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Molecular Genetics & Metabolism. 2004;83:280–286
  4. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: Insights from experimental data and clinical studies. Diabetes Metabolism. 2000;26:254–264
  5. Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes. 1994;43:441–446
  6. Colhoun HM, Lee ET, Bennett PH, Lu M, Keen H, Wang SL, et al. Risk factors for renal failure: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S46–S53
  7. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 1993;16:1376–1383
  8. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352:213–219
  9. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A–V gene and the serum triglyceride level in Japanese schoolchildren. Human Genetics. 2002;111:570–572
  10. Fagot-Campagna A, Nelson RG, Knowler WC, Pettitt DJ, Robbins DC, Go O, et al. Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians: The Strong Heart Study. Diabetologia. 1998;41:1002–1009
  11. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochemical & Biophysical Research Communications. 2004;319:397–404
  12. Giorgino F, Laviola L, Cavallo PP, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: The EURODIAB Prospective Complications Study. Diabetologia. 2004;47:1020–1028
  13. Hadjadj S, Duly-Bouhanick B, Bekherraz A, Brldoux F, Gallois Y, Mauco G, et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metabolism. 2004;30:43–51
  14. Iseki K, Tozawa M, Ikemiya Y, Kinjo K, Iseki C, Takishita S. Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort. Clinical & Experimental Nephrology. 2005;9:46–52
  15. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, et al. Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney International. 2003;64:817–828
  16. Kim DM, Ahn CW, Park JS, Cha BS, Lim SK, Kim KR, et al. An implication of hypertriglyceridemia in the progression of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes mellitus in Korea. Diabetes Research & Clinical Practice. 2004;66(Suppl 1):S169–S172
  17. Martin S, Nicaud V, Humphries SE, Talmud PJ. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochimica et Biophysica Acta. 2003;1637:217–225
  18. Masana L, Ribalta J, Salazar J, Fernandez-Ballart J, Joven J, Cabezas MC. The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects. Clinical Chemistry & Laboratory Medicine. 2003;41:517–521
  19. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase. Journal of Biological Chemistry. 2005;280:21553–21560
  20. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney International. 2000;58:293–301
  21. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney International. 1999;(Suppl 71):S51–S53
  22. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clinical Chemistry. 2005;51:351–359
  23. Orchard TJ, Forrest KY, Kuller LH, Becker DJ. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053–1059
  24. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169–173
  25. Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 (author's translation), Diabete Metab. 1977;3:97–107
  26. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Archives of Internal Medicine. 1998;158:998–1004
  27. Rogus JJ, Warram JH, Krolewski AS. Genetic studies of late diabetic complications: The overlooked importance of diabetes duration before complication onset. Diabetes. 2002;51:1655–1662
  28. Sambrook J, Fritsch E, Maniatis T. In: Molecular cloning: A laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989;p. E3–E4
  29. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. New England Journal of Medicine. 1989;320:1161–1165
  30. van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, et al. Adenoviral overexpression of apolipoprotein A–V reduces serum levels of triglycerides and cholesterol in mice. Biochemical & Biophysical Research Communications. 2002;295:1156–1159
  31. Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care. 2003;26:2410–2415

PII: S1056-8727(06)00026-2

doi: 10.1016/j.jdiacomp.2006.02.003

Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 158-163 , May 2007

Article Tools